TScan Stock Skyrockets as Amgen Joins Forces for $500M Crohn’s Disease Game-Changer Treatment
Rewrite and expand this content to 900 words Shares of TScan Therapeutics Inc. TCRX powered up 43.1% in premarket trading Tuesday, after the biopharmaceutical company announced a collaboration with Amgen Inc. AMGN to treat Crohn’s disease that could be worth more than $500 million to TScan. Amgen shares slipped 0.1% ahead of the open. Under […]